as 07-26-2024 4:00pm EST
Stocks
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
Founded: | 2021 | Country: | United States |
Employees: | N/A | City: | NEWTOWN SQUARE |
Market Cap: | 653.5M | IPO Year: | 2024 |
Target Price: | $29.25 | AVG Volume (30 days): | 73.8K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.23 | EPS Growth: | N/A |
52 Week Low/High: | $14.35 - $25.95 | Next Earning Date: | 08-02-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
GORDON CARL L | AVBP | Director10% Owner | Jan 30 '24 | Buy | $18.00 | 222,222 | $3,999,996.00 | 1,513,664 | SEC Form 4 |
GORDON CARL L | AVBP | Director10% Owner | Jan 30 '24 | Buy | $18.00 | 222,222 | $3,999,996.00 | 1,513,664 | SEC Form 4 |
ORBIMED ADVISORS LLC | AVBP | Director10% Owner | Jan 30 '24 | Buy | $18.00 | 222,222 | $3,999,996.00 | 1,513,664 | SEC Form 4 |
ORBIMED ADVISORS LLC | AVBP | Director10% Owner | Jan 30 '24 | Buy | $18.00 | 222,222 | $3,999,996.00 | 1,513,664 | SEC Form 4 |
HEALY JAMES | AVBP | Director | Jan 30 '24 | Buy | $18.00 | 444,444 | $7,999,992.00 | 1,696,752 | SEC Form 4 |
HILLHOUSE INVESTMENT MANAGEMENT, LTD. | AVBP | 10% Owner | Jan 30 '24 | Buy | $18.00 | 555,555 | $9,999,990.00 | 4,484,672 | SEC Form 4 |
AVBP Breaking Stock News: Dive into AVBP Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Business Wire
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
Simply Wall St.
2 months ago
Reuters
2 months ago
AFP
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "AVBP ARRIVENT BIOPHARMA INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.